DUBLIN–(BUSINESS WIRE)–The “TRAIL Receptor 2 Agonists – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in TRAIL receptor 2 agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence TRAIL receptor 2 agonists R&D. The therapies under development are focused on novel approaches for TRAIL receptor 2 agonists.
Emerging Drugs Chapters
This segment of the TRAIL receptor 2 agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Emerging Drugs
INBRX-109: Inhibrx
INBRX-109 is a tetravalent DR5 agonistic antibody designed to exploit tumor-biased direct cell death induction by DR5 activation in numerous cancer types. With a valency of four, it has the ability to potently agonize DR5 through efficient receptor clustering, causing cell death, but by way of our sdAb platform, also eliminates recognition by pre-existing anti-drug antibodies (ADAs) to lessen the potential for hyper-clustering. In January 2021, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma.
BI 905711: Travere Therapeutics
BI 905711 is a tetravalent bispecific antibody that cross-links the pro-apoptotic tumor necrosis factor (TNF)-related apoptosis-inducing ligand receptor 2 (TRAILR2) with the tumor cell anchor cadherin 17 (CDH17). CDH17-dependent clustering of TRAILR2 allows BI 905711 to induce selective apoptosis in CDH17-expressing tumor cells. BI 905711 is currently being investigated in patients with advanced gastrointestinal (GI) cancers.
Therapeutic Assessment
This segment of the report provides insights about the different TRAIL receptor 2 agonists drugs segregated based on following parameters that define the scope of the report, such as:
Major Players
There are approx. 5+ key companies which are developing the TRAIL receptor 2 agonists. The companies which have their TRAIL receptor 2 agonists drug candidates in the most advanced stage, i.e. Phase II include, Inhibrx.
Pipeline Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TRAIL receptor 2 agonists therapeutic drugs key players involved in developing key drugs.
Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TRAIL receptor 2 agonists drugs.
Key Questions Answered
- How many companies are developing TRAIL receptor 2 agonists drugs?
- How many TRAIL receptor 2 agonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TRAIL receptor 2 agonists?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the TRAIL receptor 2 agonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for TRAIL receptor 2 agonists and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Inhibrx
- Boehringer Ingelheim
- IGM Biosciences
- Amgen
- Genmab
- Theraly Fibrosis
- IGM Biosciences
Key Products
- INBRX-109
- BI 905711
- IGM 8444
- Conatumumab
- Benufutamab
- TLY 012
- Anti-DR5 IgM antibody
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2lcta
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900